Results 241 to 250 of about 5,128,022 (309)

Decade-long protection of the mumps vaccine: Insights from a large-scale serological study. [PDF]

PLoS Negl Trop Dis
Qian Z, Chen Y, Zeng L, Liang C, Lin W, Xiong C, Li X, Deng Y, Chen L, Yang Y, Sun L, He J, Sun J.   +12 more
europepmc   +1 more source

Accelerating antibody discovery and optimization with high-throughput experimentation and machine learning. [PDF]

J Biomed Sci
Matsunaga R, Tsumoto K.
europepmc   +1 more source

Recovery of Antibody Immunity After a Resurgence of Respiratory Syncytial Virus Infections. [PDF]

J Infect Dis
Reicherz F, Viñeta Paramo M, Bone JN, Lavoie A, Li S, Golding L, Jassem A, Watts A, Abu-Raya B, Lavoie PM.   +9 more
europepmc   +1 more source

Targeting acute myeloid leukemia through antibody engineering: innovations in immunotherapy and combination regimens. [PDF]

Clin Exp Med
Soleimani Samarkhazan H, Noormohamadi H, Shafiei FS, Taghinejad Z, Maleknia M, Raoufi A, Nouri S, Mohammadi MH.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Strategies and challenges for the next generation of antibody–drug conjugates

Nature Reviews Drug Discovery, 2017
Alain Beck, Charles Dumontet
exaly   +2 more sources

Antibodies and Selection of Monoclonal Antibodies

2015
Monoclonal antibodies are universal binding molecules with a high specificity for their target and are indispensable tools in research, diagnostics and therapy. The biotechnological generation of monoclonal antibodies was enabled by the hybridoma technology published in 1975 by Köhler and Milstein.
Katrin Messerschmidt, Katja Hanack, Martin Listek   +2 more
openaire   +3 more sources